TipRanks Cyber Monday Sale
- Claim 60% off TipRanks Premium for data-backed insights and research tools you need to invest with confidence.
- Subscribe to TipRanks' Smart Investor Picks and see our data in action through our high-performing model portfolio - now also 60% off
Biofrontera ( (DE:B8FK) ) just unveiled an update.
Biofrontera AG has announced an extension of the payment deferral for receivables amounting to EUR 1.8 million from its US counterpart, Biofrontera Inc. The deferral, originally set to expire on June 18, 2025, has been extended to June 22, 2025, with a potential further extension to June 27, 2025, contingent upon the agreement on a revised license and supply agreement. This extension reflects ongoing negotiations and could impact the financial operations and strategic positioning of Biofrontera in the dermatological market.
More about Biofrontera
Biofrontera AG is a German company operating in the pharmaceutical industry, focusing on the development and commercialization of dermatological products. It is involved in the regulated markets in Dusseldorf, Frankfurt, and the free markets in Berlin, Munich, Stuttgart, and Tradegate.
Average Trading Volume: 1,505
Technical Sentiment Signal: Strong Sell
Current Market Cap: €14.77M
Learn more about B8FK stock on TipRanks’ Stock Analysis page.